HOME >> BIOLOGY >> NEWS
MGH-Led Team Finds Gene For Crippling Neurologic Disorder

A research team led by investigators from the Massachusetts General Hospital (MGH) has identified and cloned the gene responsible for early-onset dystonia, a crippling, inherited neurological disorder that begins in childhood. The discovery, announced in the September issue of Nature Genetics, is the culmination of more than 15 years of work and contains important clues that could lead to better understanding of the disease and possible preventive treatments.

There are many types of dystonia, a term that generally refers to sustained, involuntary muscle contractions that can twist and contort parts of the body. Early-onset dystonia, usually appearing before the age of 11, is the most common and severe hereditary form of the disorder, affecting about 50,000 people in North America. Symptoms usually begin in the legs or arms and spread to the rest of the body, causing it to twist into unnatural postures; symptoms worsen when patients are fatigued or stressed. Patients with advanced dystonia may be confined to a wheel-chair or bedridden. The lifelong condition is more prevalent than Huntington's disease or amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) among the general population and has a higher frequency among Ashkenazi Jews, those of Eastern European ancestry.

"We look on dystonia as a 'stealth crippler'," says Xandra O. Breakefield, PhD, of the MGH Molecular Neurogenetics Unit, leader of the research team. "In contrast to other movement disorders, like Parkinson's disease, there is no visible evidence of damage to the brain and no truly effective drug treatment. Only after identifying the responsible gene and then determining the function of its protein can we understand exactly how this disease produces its symptoms." Along with scientists from Breakefield's MGH lab, the paper's coauthors include researchers from the Columbia University College of Physicians and Surgeons and Mount Sinai School of Medicine in New York, Oregon Health S
'"/>

Contact: Susan McGreevey
mcgreeveys@al.mgh.harvard.edu
617-724-2764
Massachusetts General Hospital
3-Sep-1997


Page: 1 2 3

Related biology news :

1. Very-Low-Fat Diet May Compromise Immune Function, Increase Infection Risk In Trained Runners, UB Study Finds
2. USGS Finds Palila Population Remaining Stable
3. Breast Milk Of Women Who Eat Lake Ontario Fish Contains High Levels Of PCBs, UB Study Finds
4. UB Study Finds No Relationship Between Male Consumption Of Lake Ontario Fish And Conception Delay
5. Botanical Products Act Like Estrogen In Animals, Finds University Of Pittsburgh Team
6. Study Of Childrens Fillings Finds No Mercury Exposure
7. USGS Finds That Mysterious Arkansas Bald Eagle Disease Has Spread To Ducks In Eastern States
8. Study Finds Choline Deficiency Harms Memory Center In Mammals Brains
9. AIDS Virus May Evolve Differently In Cerebrospinal Fluid Compared With Blood In Some Patients, UCSF/Gladstone Research Finds
10. Nationwide Study Finds HIV-Positive Women Are At High Risk For Cervical Human Papillomavirus Infection
11. Study Finds Protein Clues To Early Embryo Development

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: MGH Led Team Finds Gene For Crippling Neurologic Disorder

(Date:5/21/2013)... at USC have found that a class of pharmaceuticals ... , The drugs, known as "TSPO ligands," are ... looked at the effects of TSPO ligand in young ... and in aged mice when pathology was quite severe," ... School of Gerontology. "TSPO ligand reduced measures of pathology ...
(Date:5/21/2013)... Michigan Water Center today awarded 12 research grants, ... and protection efforts. , The two-year grants of ... efforts to track the remediation of harmful algae ... non-native weedy plant invasions; study chromosomal damage in ... restoration activities. , The grants were awarded to ...
(Date:5/21/2013)... an uphill battle? Try staying fit in space, where ... and bone. , That,s the challenge a group of ... three-year, $1.2 million grant from NASA. Their goal is ... missions. , "You could give astronauts the best exercise ... to stick to it, it isn,t going to help," ...
Breaking Biology News(10 mins):Drugs found to both prevent and treat Alzheimer's disease in mice 2U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4Fueling fitness on the final frontier 2
(Date:5/22/2013)... Express Diagnostics Int’l, Inc. (EDI) , ... pleased to announce a sponsorship agreement with Erebus Motorsport ... distributor of DrugCheck® onsite testing devices, manufactured by EDI. ... Austin 400 May 17-19 in Austin, Texas. , Royal ... each car of the Erebus Motorsport team displaying the ...
(Date:5/22/2013)... Chester, PA (PRWEB) May 22, 2013 ... company as Fermentation Manager. Mr. McErlean has an ... variety of leadership positions throughout his career. ... “We are very pleased to have Mike join our ... newly installed large scale fermentation and downstream ...
(Date:5/22/2013)... 22, 2013 The ability to ... the information they encode. There are now a ... sequencing of ribosome protected fragments) that dramatically expand ... Keynote speakers include Dr. Jonathan Weissman, an Investigator ... Howard Hughes Medical Institute, who will present recent ...
(Date:5/21/2013)... 22, 2013 First patients dosed ... glycopyrronium bromide designed using Prosonix, particle engineering platform ... portfolio of inhaled Respiratory Medicines by Design , ... that will assess its effect on lung function and ... with moderate to severe chronic obstructive pulmonary disease (COPD). ...
Breaking Biology Technology:Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team 2Envera Appoints Michael McErlean Fermentation Manager 2Monitoring Protein Synthesis One Codon at a Time Through Ribosome Profiling, a Webinar Hosted by Xtalks 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4
Cached News: